SLC38A2 and triple-negative breast carcinoma: Upregulation of SLC38A2 has been observed in triple-negative breast cancer and hormone-resistant breast cancer, and it is associated with resistance to oxidative stress and the development of drug resistance, ultimately leading to poor clinical outcomes (Morotti et al., 2021; Morotti et al., 2019).